This anti-parasite medicine interferes with how cancer cells divide and has a long history of safe use in humans.
And although there have been no human brain cancer trials to date, it has been quite successful in mouse models and is now undergoing further study.
- Active Clinical Trials (1)
It is available over the counter in Europe but by prescription only in the U.S.
And as one of the four drugs used by CareOncology to treat cancer, they could be a resource to learn more as well.
Title: Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
Inclusion criteria: For those under 21 with a case of Recurrent/Progressive disease
- Johns Hopkins All Children's Hospital
Saint Petersburg, Florida, United States, 33701
- Johns Hopkins University School of Medicine
Baltimore, Maryland, United States, 21231
Principal Investigator: Kenneth J Cohen, MD
Treatment Protocol: Patients will take Mebendazole as the primary treatment in the case of Recurrence/Progression.
Title: Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
Summary: In this study, scientists tested the effects of Mebendazole on both cancer cells in the laboratory and on mice with implanted human gliomas
- The mice that were given Mebendazole lived significantly longer
- Findings suggest it is a novel treatment to be explored further for brain cancer
- It has a proven record of safe use in humans
Title: Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors
Summary: In this study, scientists tested Mebendazole against another commonly used drug that works in a similar manner to see which was more effective.
- Mebendazole increased animal survival time for those with implanted human brain tumors
- Based on the results, the authors strongly suggest the use of Mebendazole to treat brain tumors